Moreover, it has been reported that PI3K pathway inhibitors (e.g., BEZ235 and BKM120) promote expression of RSK3 and RSK4, which is associated with drug resistance and tumorigenesis in breast cancer [16]. This evidence concerns the gene RPS6KA2 and breast carcinoma.